Last Price$394.92.3%
Market Cap$150.5B
LTM Free Cash Flow
$3,487.0M
YoY Growth
+11.2%
3Y CAGR
+8.4%
5Y CAGR
+17.7%
Stock quality & Intrinsic value
7/10
22.7% overvalued
Stryker Corporation Free Cash Flow
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | $592.1M | $649.8M | $840.6M | $1,020.7M | $1,329.4M | $1,365.3M | $1,208.0M | $1,447.0M | $1,691.0M | $1,549.0M | $629.0M | $1,322.0M | $961.0M | $2,038.0M | $1,542.0M | $2,790.0M | $2,738.0M | $2,036.0M | $3,136.0M | $3,487.0M |
Overvalued or undervalued?
Check the intrinsic value for SYK
and see if it's the right time to invest.
Stryker Corporation (SYK) Free Cash Flow comparison analysis
General
LTM Free Cash Flow
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Stryker CorporationSYK
$3,487.0M
11.2%
8.4%
17.7%
Median Peer Set
$687.0M
6.6%
(0.6%)
0.7%
Abbott LaboratoriesABT
$6,351.0M
25.5%
(9.8%)
7.1%
Medtronic plcMDT
$5,467.0M
10.9%
(1.3%)
(3.9%)
Boston Scientific CorporationBSX
$2,438.0M
43.2%
22.8%
14.5%
Zimmer Biomet Holdings, Inc.ZBH
$1,132.4M
0.6%
(5.2%)
0.5%
STERIS plcSTE
$751.4M
26.5%
22.2%
17.2%
Align Technology, Inc.ALGN
$622.7M
2.4%
(6.9%)
0.8%
Edwards Lifesciences CorporationEW
$502.2M
(36.3%)
(29.1%)
(9.0%)
DexCom, Inc.DXCM
$453.9M
(11.3%)
104.2%
27.5%
Insulet CorporationPODD
$303.0M
737.0%
N/A
N/A
Koninklijke Philips N.V.PHG
$296.4M
N/A
N/A
N/A
SYK key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 4,871.5 14.3% | 5,405.6 11.0% | 6,000.5 11.0% | 6,718.2 12.0% | 6,723.1 0.1% | 7,320.0 8.9% | 8,307.0 13.5% | 8,657.0 4.2% | 9,021.0 4.2% | 9,675.0 7.2% | 9,946.0 2.8% | 11,325.0 13.9% | 12,444.0 9.9% | 13,601.0 9.3% | 14,884.0 9.4% | 14,351.0 (3.6%) | 17,108.0 19.2% | 18,449.0 7.8% | 20,498.0 11.1% | 22,595.0 10.2% |
| Cost of Goods Sold (COGS) | 1,713.9 | 1,848.7 | 1,865.2 | 2,131.4 | 2,183.7 | 2,285.7 | 2,811.0 | 2,781.0 | 2,977.0 | 3,291.0 | 3,344.0 | 3,830.0 | 4,271.0 | 4,663.0 | 5,188.0 | 5,294.0 | 6,140.0 | 6,871.0 | 7,401.0 | 8,155.0 |
% margin | 3,157.6 64.8% | 3,556.9 65.8% | 4,135.3 68.9% | 4,586.8 68.3% | 4,539.4 67.5% | 5,034.3 68.8% | 5,496.0 66.2% | 5,876.0 67.9% | 6,044.0 67.0% | 6,384.0 66.0% | 6,602.0 66.4% | 7,495.0 66.2% | 8,173.0 65.7% | 8,938.0 65.7% | 9,696.0 65.1% | 9,057.0 63.1% | 10,968.0 64.1% | 11,578.0 62.8% | 13,097.0 63.9% | 14,440.0 63.9% |
| Operating Expenses | 2,142.9 | 2,429.9 | 2,828.0 | 3,032.9 | 2,878.0 | 3,159.4 | 3,734.0 | 4,060.0 | 4,740.0 | 5,138.0 | 4,445.0 | 5,171.0 | 5,710.0 | 6,378.0 | 6,791.0 | 6,817.0 | 8,281.0 | 8,536.0 | 9,209.0 | 10,751.0 |
| Research & Development Expenses (R&D) | 279.8 | 324.6 | 375.3 | 367.8 | 336.2 | 393.9 | 462.0 | 471.0 | 536.0 | 614.0 | 625.0 | 715.0 | 787.0 | 862.0 | 971.0 | 984.0 | 1,235.0 | 1,454.0 | 1,388.0 | 1,466.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,814.3 | 2,061.7 | 2,391.5 | 2,625.1 | 2,506.3 | 2,707.3 | 3,150.0 | 3,466.0 | 4,066.0 | 4,336.0 | 3,610.0 | 4,137.0 | 4,552.0 | 5,099.0 | 5,356.0 | 5,361.0 | 6,427.0 | 6,455.0 | 6,920.0 | 7,685.0 |
% margin | 998.8 20.5% | 1,074.3 19.9% | 1,307.3 21.8% | 1,519.0 22.6% | 1,594.4 23.7% | 1,751.4 23.9% | 1,686.0 20.3% | 1,741.0 20.1% | 1,256.0 13.9% | 1,246.0 12.9% | 1,861.0 18.7% | 2,166.0 19.1% | 2,290.0 18.4% | 2,537.0 18.7% | 2,713.0 18.2% | 2,223.0 15.5% | 2,584.0 15.1% | 2,841.0 15.4% | 3,888.0 19.0% | 3,689.0 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 34.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 155.0 | 102.0 | 68.0 | 94.0 | 75.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 34.8 | 52.6 | 0.0 | 0.0 | 34.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 287.0 | 315.0 | 337.0 | 158.0 | 356.0 | 0.0 |
| Pre-tax Income | 1,003.3 | 1,103.8 | 1,370.1 | 1,580.2 | 1,623.9 | 1,729.6 | 1,686.0 | 1,705.0 | 1,212.0 | 1,160.0 | 1,735.0 | 1,921.0 | 2,063.0 | 2,356.0 | 2,562.0 | 1,954.0 | 2,281.0 | 2,683.0 | 3,673.0 | 3,492.0 |
% effective tax rate | 328.1 32.7% | 326.1 29.5% | 383.4 28.0% | 432.4 27.4% | 516.5 31.8% | 456.2 26.4% | 341.0 20.2% | 407.0 23.9% | 206.0 17.0% | 645.0 55.6% | 296.0 17.1% | 274.0 14.3% | 1,043.0 50.6% | (1,197.0) (50.8%) | 479.0 18.7% | 355.0 18.2% | 287.0 12.6% | 325.0 12.1% | 508.0 13.8% | 499.0 14.3% |
% margin | 675.2 13.9% | 777.7 14.4% | 1,017.4 17.0% | 1,147.8 17.1% | 1,107.4 16.5% | 1,273.4 17.4% | 1,345.0 16.2% | 1,298.0 15.0% | 1,006.0 11.2% | 515.0 5.3% | 1,439.0 14.5% | 1,647.0 14.5% | 1,020.0 8.2% | 3,553.0 26.1% | 2,083.0 14.0% | 1,599.0 11.1% | 1,994.0 11.7% | 2,358.0 12.8% | 3,165.0 15.4% | 2,993.0 13.2% |
| EPS | 1.60 | 1.91 | 2.48 | 2.81 | 2.79 | 3.21 | 3.48 | 3.41 | 2.66 | 1.36 | 3.82 | 4.40 | 2.73 | 9.50 | 5.57 | 4.26 | 5.29 | 6.23 | 8.34 | 7.86 |
| Diluted EPS | 1.57 | 1.89 | 2.44 | 2.78 | 2.77 | 3.19 | 3.45 | 3.39 | 2.63 | 1.34 | 3.78 | 4.35 | 2.68 | 9.34 | 5.48 | 4.20 | 5.22 | 6.17 | 8.25 | 7.76 |
% margin | 1,252.2 25.7% | 1,445.1 26.7% | 1,758.9 29.3% | 1,998.3 29.7% | 2,023.7 30.1% | 2,217.3 30.3% | 2,261.0 27.2% | 2,049.0 23.7% | 2,353.0 26.1% | 2,604.0 26.9% | 2,667.0 26.8% | 3,126.0 27.6% | 3,363.0 27.0% | 3,617.0 26.6% | 4,176.0 28.1% | 3,755.0 26.2% | 4,646.0 27.2% | 4,536.0 24.6% | 4,934.0 24.1% | 5,716.0 25.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Stryker Corporation's Free Cash Flow?
As of today, Stryker Corporation's last 12-month Free Cash Flow is $3,487.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Stryker Corporation's Free Cash Flow growth rate?
Over the last year, Stryker Corporation's Free Cash Flow growth was 11.2%. The average annual Free Cash Flow growth rates for Stryker Corporation have been 5.5% over the past three years, 17.7% over the past five years.
3) Is Stryker Corporation's Free Cash Flow growth rate Good?
Over the last year, Stryker Corporation's Free Cash Flow growth was 11.2%, which is higher than industry growth of (0.3%). It indicates that Stryker Corporation's Free Cash Flow growth is Good.